Sanofi's iniparib misses primary endpoints in newly diagnosed triple negative breast cancer

Published by Sally Church on Pharma Strategy Blog


Sanofi-aventis have just announced :

“A randomized Phase III trial evaluating BSI-201 (iniparib*) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival.”

Iniparib was thought to offer the best chance of success with PARP inhibitors because the others have so far been shown to be

  1. more potent
  2. more challenging to combine given the toxicities involved.

Clearly it is a fine line between potency and toxicities with this particular class.

Click here to read the full post on Pharma Strategy Blog

, , , , , , , , , , , , , , ,

error: Content is protected !!